ARPA‑H has awarded the University of California San Diego roughly $25.8 million to develop patient‑specific, 3D‑bioprinted human livers under the agency’s PRINT program. The multidisciplinary effort, led by Shaochen Chen, will combine high‑resolution rapid bioprinting with AI‑driven vascular design to scale from tissue patches to transplant‑sized organs. The project aims to deliver a manufacturing pathway for on‑demand liver grafts and reduce dependence on donor organs. The team will integrate rapid fabrication methods and computational vascular engineering to address perfusion and scaling constraints that have blocked clinical translation. ARPA‑H funding covers a 60‑month program intended to move toward functional, transplantable tissue capable of restoring liver function without long‑term immunosuppression. Bioprinting here refers to layer‑by‑layer deposition of cell‑laden biomaterials and supporting matrices to recreate organ microarchitecture, including blood vessel networks necessary for survival of large constructs.